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Abstract
We investigated the association of metabolic syndrome (MetS) with a 500 k and a 50 k single-
nucleotide polymorphism (SNP) gene chip in the Framingham Heart Study. We cross-sectionally
evaluated the MetS longitudinal trends. Data analyzed were from the Offspring Cohort (four
exams: first (n = 2,441), third (n = 2,185), fifth (n = 2,308), and seventh (n = 2,328)) and the
Generation 3 Cohort (one exam: the first exam (n = 3,997)). The prevalence of MetS was
determined using the National Cholesterol Education Program Adult Treatment Panel III diagnostic
criteria, modified with a newly developed correction for medication use. The association test
between an SNP and MetS was performed with a generalized estimating equations method under
the additive genetic model. Multiple-testing corrections were also performed. The prevalence of
MetS in the offspring cohort increased from one visit to the next, and reached the highest point by
the seventh exam comparable with the prevalence reported for the general US population. The
pattern of the MetS prevalence over time also reflected itself in the association tests, in which the
highest significances were seen in the fifth and seventh exams. The association tests showed that
SNPs within genes PRDM16, CETP, PTHB1, PAPPA,a n dFBN3, and also some SNPs not in genes were
significant or close to significance at the genome-wide thresholds. These findings are important in
terms of eventually identifying with the causal loci for MetS.
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Metabolic syndrome (MetS) is characterized by abdom-
inal obesity, dyslipidemia, elevated blood pressure,
insulin resistance, glucose intolerance, and possibly a
prothrombotic and proinflammatory state [1]. MetS is a
rising global public health problem because of its role in
increasing the risk of cardiovascular disease and diabetes
mellitus [2]. In addition to the lifestyle or environmental
risk factors, much evidence has shown that common
genetic variants predispose individuals to development
of MetS [3]. Framingham Heart Study (FHS) is one of the
best-known cohort studies of cardiovascular disease that
has demonstrated an association between cardiovascular
risk factors and cardiovascular disease [4]. In the current
study we investigated the longitudinal trends in MetS
association with a 500 k and 50 k single-nucleotide
polymorphisms (SNPs) in the FHS datasets.
Methods
Sampled data and MetS definition
The FHS data comprised three generations of long-
itudinal measurements. The first dataset is the “Original
Cohort”, the second dataset is the “Offspring Cohort”
and the third dataset is the “Generation 3 Cohort”.W e
analyzed data from the Offspring Cohort and the
Generation 3 Cohort. The data of Original Cohort were
excluded due to missing variables related to MetS.
Longitudinal analysis for the prevalence of MetS and
its components was performed in each of the four exams
(first (n = 2,441), third (n =2 , 1 8 5 ) ,f i f t h( n = 2,308), and
seventh (n = 2,328) exams) of the Offspring Cohort, and
a cross-sectional analysis was performed in the first exam
(n = 3,997) of the Generation 3 Cohort. The prevalence
of MetS was identified using the National Cholesterol
Education Program (NCEP) modified diagnostic criteria
with a newly developed correction for medication use
[1]. One exception was that the waist circumference was
not available in the FHS data distributed through
Genetic Analysis Workshop 16. Therefore, we substituted
it with the body mass index (BMI) criteria for obesity.
Previous publications have shown that BMI is highly
correlated with the waist circumference [5]. An indivi-
dual with a combination of any three or more of the
following risk factors was classified as having MetS:
BMI ≥ 30 kg/m
2; triglyceride (TG) ≥ 150 mg/dl; high-
density lipoprotein cholesterol (HDLC) < 40 mg/dl in
men and < 50 mg/dl in women; systolic blood pressure
(SBP) or diastolic blood pressure (DBP) ≥ 130/85 mm
Hg or use of anti-hypertensive medications; and fasting
blood glucose (GLUC) ≥ 110 mg/dl or use of anti-
diabetic medications with the age of diagnosis with
diabetes mellitus ≥ 40 years. The modified NCEP
diagnostic criteria were applied to consider the partici-
pants medication use. Thus, TG and HDL for the subjects
treated with antihyperlipidemics were corrected to new
values based on the following formula: TG/(1-15.2/
100), HDLC/(1+6.1/100) (mg/dl). The SBP and DBP for
subjects using antihypertensives were corrected to new
values based on the following formula: SBP+14.8 and
DBP+10.5 (mm Hg). These formulas were based on
previous research, which represent corrections of a
participant’s medicated traits based on the mean values
of many summarized treatment clinical trials [6-8].
Statistical analysis
The qualitative MetS variable, which took medication
use into account, was used to test its association with
both the genome-wide scan 500 k SNPs and the
additional 50 k gene SNPs, for a total of approximately
550 k SNPs (GeneChip® Human Mapping 500 k Array
S e ta n dt h e5 0kH u m a nG e n eF o c u s e dP a n e l ) .T h e
genotype data were recoded based on the additive
model. A logistic regression of recoded genotype on
MetS, based on the generalized estimating equation
statistical model to account for the familial relationships
among subjects within a pedigree, was performed using
PROC GENMOD of SAS v 9.1.3 applying parallel
computing with Platform SAS under Linux OS. In order
to address multiple testing correction issues, we applied
the simpleM method, which is an effective number of
independent tests approach based on principal-compo-
nent analysis that takes into account linkage disequili-
brium (LD) information among SNPs [9]. The inferred
effective number of independent tests for the 500 k chip
was 281,502. Therefore, the genome-wide threshold for
declaring significance for this data was a p-value ≤ 1.78 ×
10
-7.F o rt h e5 0kc h i p ,b a s e do nt h es a m em e t h o dt h e
significance threshold was 1.29 × 10
-6. We considered
these two chip results separately because they represent
independent chips and also our analyses per type of chip
were performed independent of each other.
Results
MetS: trends in prevalence
The mean (range) age of subjects at the first, third, fifth,
and seventh exam in the Offspring Cohort was 33.6
(9-60), 46.2 (21-72), 53.1 (28-79), and 60.1 (35-85)
years,respectively.Themean(range)ageofsubjectsinthe
Generation 3 Cohort was 40.2 (19-72) years. The
prevalence of MetS at the first, third, fifth, and seventh
examintheoffspringcohortwas10.9%,15%,23.7%,and
23.6%, respectively. The prevalence of MetS at first exam
in the Generation 3 Cohort was 14.2%. The prevalence of
subjectshavingfourandfivecomponentsofMetSbeyond
their threshold increased with the number of exams,
while the prevalence of subjectshaving three components
beyond the threshold decreased on the seventh exam
(Figure 1). Particularly, the prevalence of high BMI, high
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highGLUCincreasedwiththeexams,exceptfortheGLUC
at first exam. The changes in HDL prevalence had no
particular trend.
Association analysis
The association tests showed that a few SNPs within
genes PRDM16, CETP, PTHB1, PAPPA,a n dFBN3,a n d
also some SNPs not in genes, were significant or close to
significance at the genome-wide thresholds for different
exams in the Offspring Cohort and a few in the
Generation 3 Cohort (Table 1). If the primary significant
association MetS-SNP for a particular gene was from the
50 k chip, then we found that the 500 k chip for each
gene reported had other SNPs that also were significant
but did not reach the ultimate genome-wide thresholds.
The same was observed when the primary significant
association was from the 500 k. The 500 k significant
SNPs findings were supported from other SNPs of the
same gene on 50 k chip, but they did not pass the
genome-wide thresholds. Due to space restriction, we do
not report these findings.
Discussion
The longitudinal trends of MetS prevalence and of the
association tests were evaluated by using the cross-
sectional phenotypic measurements. The prevalence of
MetS in the Offspring Cohort increased from one visit to
the next, and reached the highest point by the seventh
exam, comparable with reported MetS prevalence of the
U Sp o p u l a t i o n[ 2 ] .T h ep r e v a l e n c eo fM e t Sw a sa l s oh i g h
in the young people (Generation 3 Cohort), driven
mostly by the increase in obesity. This pattern was also
seen in the association results, where the highest
significance values were found in analysis of the later
exams (fifth and seventh). SNP rs17390167, part of the
gene PRDM16 on chromosome 1, was close to the
significance threshold of the 50 k chip. This gene recently
is reported to be the principal regulator of brown
adipocyte tissue formation and function [10,11].
Another interesting finding was the association of
rs11508026, a SNP on the CETP (cholesteryl ester
transfer protein) gene, with the MetS. This gene is
already studied extensively for its inhibitors, because
inhibition of CETP elevates the fraction of plasma
Figure 1
Trends of MetS prevalence in the FHS. The prevalence of MetS in the Offspring Cohort tended to increase with the
number of exams and reached the highest point on the fifth and seventh exam, comparable with the MetS prevalence of the
general US population.
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Exam 21a Exam 23 Exam 25 Exam 27 Exam 31
Marker Chr Position
(bp)
Hugo Role MAF
(%)
Estimate STD
error
c
2
p-value
Estimate STD
error
c
2
p-value
Estimate STD
error
c
2
p-value
Estimate STD
error
c
2
p-value
Estimate STD
error
c
2
p-value
50 k
rs17390167 1 3084691 PRDM16 Intron 5.2 -0.01 0.02 4.9 × 10
-1 -0.06 0.03 1.8 × 10
-2 -0.14 0.03 3.8 × 10
-6 -0.04 0.03 1.4 × 10
-1 -0.01 0.02 4.6 × 10
-1
rs11508026 16 55556829 CETP Intron 42.5 -0.02 0.01 1.1 × 10
-1 -0.04 0.01 2.0 × 10
-4 -0.04 0.01 2.7 × 10
-3 -0.07 0.01 7.2 × 10
-7 -0.01 0.01 1.6 × 10
-1
500 k
(in genes)
rs13241465 7 33473074 PTHB1 Intron 32.6 0.00 0.01 8.8 × 10
-1 0.02 0.01 1.8 × 10
-1 0.08 0.01 1.4 × 10
-8 0.03 0.01 1.3 × 10
-2 0.03 0.01 1.3 × 10
-3
rs4236337 7 33473431 PTHB1 Intron 32.4 0.00 0.01 9.2 × 10
-1 0.02 0.01 1.6 × 10
-1 0.08 0.01 2.8 × 10
-8 0.03 0.01 1.9 × 10
-2 0.03 0.01 2.4 × 10
-3
rs4509212 7 33473170 PTHB1 Intron 31.4 0.00 0.01 9.4 × 10
-1 0.02 0.01 7.2 × 10
-2 0.07 0.01 6.2 × 10
-8 0.03 0.01 1.5 × 10
-2 0.02 0.01 1.3 × 10
-2
rs2418441 9 118114658 PAPPA Intron 1.0 -0.02 0.04 6.7 × 10
-1 0.01 0.05 8.4 × 10
-1 0.06 0.06 3.3 × 10
-1 -0.03 0.06 5.9 × 10
-1 -0.25 0.04 1.2 × 10
-8
rs10408896 19 8124201 FBN3 Promoter 0.1 0.03 0.14 8.3 × 10
-1 0.41 0.16 1.0 × 10
-2 0.12 0.19 5.4 × 10
-1 0.12 0.19 5.4 × 10
-1 0.49 0.09 8.8 × 10
-8
500 k
(not in genes)
rs318256 8 8.2 -0.01 0.02 4.6 × 10
-1 0.00 0.02 9.2 × 10
-1 0.02 0.02 4.4 × 10
-1 0.01 0.02 7.2 × 10
-1 0.08 0.01 1.5 × 10
-7
rs1431573 11 126981969 43.9 -0.01 0.01 5.5 × 10
-1 -0.06 0.01 1.4 × 10-
7c -0.03 0.01 7.8 × 10
-3 -0.02 0.01 1.9 × 10
-1 0.00 0.01 9.4 × 10
-1
rs17037068 12 104333075 1.7 0.10 0.04 3.7 × 10
-3b 0.27 0.04 5.3 × 10
-10 0.14 0.05 9.1 × 10
-3 0.14 0.05 4.2 × 10
-3 -0.03 0.03 2.9 × 10
-1
rs12437159 14 45882211 44.6 -0.02 0.01 6.7 × 10
-3 -0.04 0.01 6.2 × 10
-5 -0.06 0.01 4.3 × 10
-7 -0.08 0.01 1.0 × 10
-9 0.00 0.01 9.1 × 10
-1
rs12147964 14 45888772 42.5 -0.02 0.01 9.8 × 10
-3 -0.04 0.01 2.7 × 10
-4 -0.07 0.01 2.7 × 10
-8 -0.08 0.01 7.7 × 10
-11 0.00 0.01 8.6 × 10
-1
rs2899976 14 45893237 41.8 -0.02 0.01 1.3 × 10
-2 -0.04 0.01 9.5 × 10
-4 -0.07 0.01 2.0 × 10
-7 -0.08 0.01 2.3 × 10
-10 0.00 0.01 9.1 × 10
-1
rs11625735 14 45895075 41.8 -0.02 0.01 1.4 × 10
-2 -0.04 0.01 4.7 × 10
-4 -0.07 0.01 9.4 × 10
-8 -0.08 0.01 1.8 × 10
-10 0.00 0.01 9.0 × 10
-1
rs2010338 14 45895631 41.8 -0.02 0.01 8.9 × 10
-3 -0.04 0.01 3.4 × 10
-4 -0.07 0.01 4.2 × 10
-8 -0.08 0.01 1.5 × 10
-10 0.00 0.01 7.4 × 10
-1
rs2415974 14 45906862 42.0 -0.02 0.01 7.1 × 10
-3 -0.04 0.01 3.0 × 10
-4 -0.07 0.01 1.2 × 10
-7 -0.08 0.01 6.8 × 10
-11 0.00 0.01 7.8 × 10
-1
rs8009432 14 45917176 41.7 -0.02 0.01 1.4 × 10
-2 -0.04 0.01 4.4 × 10
-4 -0.07 0.01 1.2 × 10
-7 -0.08 0.01 3.1 × 10
-10 0.00 0.01 8.6 × 10
-1
rs10498398 14 45937239 41.1 0.02 0.01 9.8 × 10
-3 0.04 0.01 1.0 × 10
-3 0.07 0.01 8.6 × 10
-8 0.08 0.01 1.7 × 10
-9 0.00 0.01 8.4 × 10
-1
rs8019899 14 45952022 41.3 0.02 0.01 5.6 × 10
-3 0.04 0.01 1.1 × 10
-3 0.07 0.01 1.2 × 10
-7 0.07 0.01 3.0 × 10
-9 0.00 0.01 8.1 × 10
-1
aExam 21, 2 is the Offspring Cohort, and 1 is the first exam.
bBold, p-values support a significance tend, but do not reach the threshold.
bItalic, p-values that pass the significance threshold and support genome-wide significance.
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)cholesterol associated with HDL [12]. SNPs rs13241465,
rs4236337, and rs4509212 are part of the PTHB1 gene.
This gene is known also as BBS9 gene and recognized as
one of the recent Bardet-Biedl syndrome genes. Such
gene polymorphisms are hypothesized to contribute to
human obesity and diabetes mellitus [13].
In the Generation 3 Cohort first exam, the prevalence of
MetS was moderate and comparable with those of the
first and third exams of the Offspring Cohort. As a result,
only a few associations were highly significant. The SNPs
rs2418441 (PAPPA) and rs10408896 (FBN3)w e r e
highly significant, but at the same time one must be
cautious when considering them as candidate genes for
MetS, because of the rare minor allele frequency. Despite
the rarity of minor allele frequency for the above two
SNPs, PAPPA gene, a metalloproteinase, is reported to
regulate the human atherosclerotic plaque [14]; FBN3
(Fibrilin 3) is reported to contribute in the polycystic
ovary syndrome, which is associated with obesity [15].
Several other SNPs with p-values close to significance
from the same genes mentioned in the Results and
Discussion were present in the FHS data. For space
r e a s o n sw ed i dn o tr e p o r ta n yo ft h e m .F i n a l l y ,w ew o u l d
like to draw readers attention to a number of SNPs
located on chromosome 14 (rs12437159, rs12147964,
rs2899976, rs11625735, rs2010338, rs2415974,
rs8009432, rs10498398, and rs8019899), which
although not located on genes, still were associated
highly with MetS.
Conclusion
These findings are important for identifying the role of
the genes reported to be associated with MetS. As such,
they need to be further investigated in conjunction with
the quantitative risk factors of MetS.
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